End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
750,000 KRW | -1.32% | +2.74% | -1.32% |
Jun. 06 | Novartis, Roche, Biogen, Samsung Bioepis in Italy Eye-Medicine Probe | DJ |
May. 31 | Samsung Biologics Aims to Lower Greenhouse Gas Emissions by 2030 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 52% by 2026.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 54.74 and 46.44 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.32% | 38.74B | A- | ||
+0.82% | 91.94B | A- | ||
-12.88% | 32.82B | B- | ||
+64.77% | 26.66B | A | ||
-16.31% | 15.32B | C | ||
-5.78% | 13.3B | B- | ||
-11.38% | 11.65B | D+ | ||
+173.10% | 10.37B | D | ||
-49.84% | 10.12B | B | ||
+5.24% | 9.06B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A207940 Stock
- Ratings Samsung Biologics Co.,Ltd.